Publications (177) Alberto Carmona Bayonas publications View referenced research data.

filter_list

2025

  1. Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 31, Núm. 22, pp. 4655-4663

  2. Derivation and validation of the Caravaggio score for the risk stratification for recurrence in patients with cancer-associated venous thromboembolism

    European Journal of Internal Medicine, Vol. 137, pp. 67-72

  3. Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry

    Journal of Clinical Endocrinology and Metabolism, Vol. 110, Núm. 11, pp. 3155-3167

  4. Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis

    British Journal of Cancer

  5. Dysfunctional mismatch repair in patients with early triple-negative breast cancer

    Clinical and Translational Oncology, Vol. 27, Núm. 10, pp. 3924-3937

  6. External validation of a prediction model for bleeding events in anticoagulated cancer patients with venous thromboembolism (PredictAI)

    Clinical and Translational Oncology, Vol. 27, Núm. 10, pp. 4031-4039

  7. External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapy

    European journal of endocrinology, Vol. 193, Núm. 2, pp. 320-328

  8. Prospective study of the real impact of fusion centered genomic assays in patient management in a national collaborative group: the GETHI-XX-16 study

    Clinical and Translational Oncology, Vol. 27, Núm. 6, pp. 2719-2730

  9. Spanish consensus on the diagnosis and management of adrenocortical carcinoma

    Endocrine-Related Cancer, Vol. 32, Núm. 5

  10. Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial

    ESMO Open, Vol. 10, Núm. 12

  11. The role of baseline and persistent depression in adjuvant cancer therapy: impact on toxicity and quality of life

    International journal of clinical and health psychology, Vol. 25, Núm. 4, pp. 151-160

  12. Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: Data from the PANDORA-TTD20 study

    Oncologist, Vol. 30, Núm. 8

  13. Toward risk-adjusted CT schedules in first-line metastatic colorectal cancer

    Annals of Oncology

  14. Treatment and Outcomes in Advanced Gastroesophageal Adenocarcinoma in the Pre-Immunotherapy Era Based on the Spanish AGAMENON-SEOM Registry

    Cancers, Vol. 17, Núm. 13

  15. Venous thrombosis in lung cancer compared with other tumors: results from the TESEO-SEOM registry

    Thrombosis research, Vol. 256, pp. 109525

2024

  1. Cabozantinib plus atezolizumab in locally advanced/metastatic adrenocortical carcinoma: Results from a multi-cohort basket phase II trial, CABATEN/GETNE-T1914.

    Journal of Clinical Oncology, Vol. 42, Núm. 4, pp. 1-1

  2. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

    British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787

  3. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry

    Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145

  4. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686

  5. Physical Activity in Patients with Advanced Cancer: Sociodemographic, Clinical, and Psychological Correlates

    Brain Sciences, Vol. 14, Núm. 6